Bridgebio Pharma Stock Performance
| BBIO Stock | USD 32.59 0.25 0.77% |
On a scale of 0 to 100, BridgeBio Pharma holds a performance score of 7. The firm shows a Beta (market volatility) of -0.32, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning BridgeBio Pharma are expected to decrease at a much lower rate. During the bear market, BridgeBio Pharma is likely to outperform the market. Please check BridgeBio Pharma's jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether BridgeBio Pharma's price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BridgeBio Pharma are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady forward indicators, BridgeBio Pharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 394.7 M |
BridgeBio |
BridgeBio Pharma Relative Risk vs. Return Landscape
If you would invest 2,749 in BridgeBio Pharma on December 13, 2024 and sell it today you would earn a total of 500.50 from holding BridgeBio Pharma or generate 18.21% return on investment over 90 days. BridgeBio Pharma is currently generating 0.3553% in daily expected returns and assumes 3.9797% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than BridgeBio, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BridgeBio Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BridgeBio Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BridgeBio Pharma, and traders can use it to determine the average amount a BridgeBio Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0893
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BBIO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.98 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.36 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average BridgeBio Pharma is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BridgeBio Pharma by adding it to a well-diversified portfolio.
BridgeBio Pharma Fundamentals Growth
BridgeBio Stock prices reflect investors' perceptions of the future prospects and financial health of BridgeBio Pharma, and BridgeBio Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BridgeBio Stock performance.
| Return On Equity | -17.9 | ||||
| Return On Asset | -0.48 | ||||
| Profit Margin | (2.41) % | ||||
| Operating Margin | (37.63) % | ||||
| Current Valuation | 7.2 B | ||||
| Shares Outstanding | 190.19 M | ||||
| Price To Earning | (13.72) X | ||||
| Price To Book | 123.68 X | ||||
| Price To Sales | 27.72 X | ||||
| Revenue | 221.9 M | ||||
| EBITDA | (436.83 M) | ||||
| Cash And Equivalents | 715.71 M | ||||
| Cash Per Share | 4.83 X | ||||
| Total Debt | 9.2 M | ||||
| Debt To Equity | 4.61 % | ||||
| Book Value Per Share | (7.72) X | ||||
| Cash Flow From Operations | (520.73 M) | ||||
| Earnings Per Share | (2.88) X | ||||
| Total Asset | 919.34 M | ||||
| Retained Earnings | (3.1 B) | ||||
| Current Asset | 513.67 M | ||||
| Current Liabilities | 51.37 M | ||||
About BridgeBio Pharma Performance
By examining BridgeBio Pharma's fundamental ratios, stakeholders can obtain critical insights into BridgeBio Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that BridgeBio Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. Bridgebio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 576 people.Things to note about BridgeBio Pharma performance evaluation
Checking the ongoing alerts about BridgeBio Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BridgeBio Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BridgeBio Pharma had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 221.9 M. Net Loss for the year was (543.35 M) with profit before overhead, payroll, taxes, and interest of 218.02 M. | |
| BridgeBio Pharma currently holds about 715.71 M in cash with (520.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.83. | |
| Over 91.0% of the company shares are held by institutions such as insurance companies |
- Analyzing BridgeBio Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BridgeBio Pharma's stock is overvalued or undervalued compared to its peers.
- Examining BridgeBio Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BridgeBio Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BridgeBio Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BridgeBio Pharma's stock. These opinions can provide insight into BridgeBio Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.